TriVascular raises $7.2 million in venture capital
Santa Rosa biotech company TriVascular has raised $7.2 million in fresh venture capital as it runs US clinical trials on a new medical device.
Venture capital investment in cleantech totaled $1.2bn in 85 deals in the second quarter of 2009, up from $836m in 59 deals in the first quarter of 2009, according to a new report.